These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6269426)

  • 1. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms.
    Francke EL; Neu HC
    Am J Med; 1981 Sep; 71(3):435-42. PubMed ID: 6269426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftriaxone in the treatment of serious infections, particularly after surgery.
    Scully BE; Neu HC
    Am J Surg; 1984 Oct; 148(4A):35-40. PubMed ID: 6091479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftizoxime: a beta-lactamase-stable, broad-spectrum cephalosporin. Pharmacokinetics, adverse effects and clinical use.
    Neu HC
    Pharmacotherapy; 1984; 4(2):47-60. PubMed ID: 6326062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Carmine AA; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Mar; 25(3):223-89. PubMed ID: 6303743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of gram-negative bacillary meningitis: role of the new cephalosporin antibiotics.
    Cherubin CE; Corrado ML; Nair SR; Gombert ME; Landesman S; Humbert G
    Rev Infect Dis; 1982; 4 Suppl():S453-64. PubMed ID: 6294799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response.
    Thornsberry C; Jones RN; Barry AL; Fuchs PC
    Rev Infect Dis; 1982; 4 Suppl():S316-24. PubMed ID: 6294780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of cefotaxime in the treatment of surgical infections.
    Wittmann DH
    Diagn Microbiol Infect Dis; 1995; 22(1-2):173-82. PubMed ID: 7587036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ceftriaxone in serious bacterial infections.
    Epstein JS; Hasselquist SM; Simon GL
    Antimicrob Agents Chemother; 1982 Mar; 21(3):402-6. PubMed ID: 6285809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with cefotaxime in infections caused by gram-positive pathogens, especially Staphylococcus aureus.
    Fujii R
    Infection; 1985; 13 Suppl 1():S9-13. PubMed ID: 4055062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefotaxime: clinical and bacteriologic evaluation.
    Saroglou G; Paniara-Volika O; Sima A; Koltsida K; Rokas S; Kontomichalou P
    Clin Ther; 1981; 4(3):201-11. PubMed ID: 6272994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefmenoxime. Clinical, bacteriologic, and pharmacologic studies.
    LeFrock JL; Molavi A; McCloskey RV; Rolston K; Chandrasekar P; Henao L; Smith BR; Kannangara W; Schell RF; Carr BB
    Am J Med; 1984 Jul; 77(1):72-8. PubMed ID: 6331163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of cefotaxime therapy in infections caused by gram-positive pathogens.
    Iannini PB
    Infection; 1985; 13 Suppl 1():S3-6. PubMed ID: 4055052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE; Neu HC
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of cefotaxime in gram-negative meningitis.
    LeFrock JL; Molavi A; Smith B; Black P; Rosenberg M; Rolston K; Brodner R; Chandrasekar P; Henao L; Kannangara DW
    Neurosurgery; 1984 Nov; 15(5):679-82. PubMed ID: 6095133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefotaxime use in pediatric infections.
    Dajani AS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):105-10. PubMed ID: 7587022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of ceftriaxone: a review.
    Cleeland R; Squires E
    Am J Med; 1984 Oct; 77(4C):3-11. PubMed ID: 6093515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefotaxime treatment of skin and skin structure infections: a multicenter study.
    LeFrock JL; McCloskey RV
    Clin Ther; 1982; 5 Suppl A():19-25. PubMed ID: 6293714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.